[Federal Register Volume 89, Number 166 (Tuesday, August 27, 2024)]
[Notices]
[Page 68584]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-19040]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

International Trade Administration


AI-Enabled Medical Technologies Industry Roundtable

AGENCY: International Trade Administration, Department of Commerce.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The International Trade Administration (ITA) of the Department 
of Commerce announces a roundtable discussion with industry 
representatives and U.S. government officials on strategies to increase 
U.S. industry competitiveness and support commercialization of U.S.-
produced artificial intelligence (AI)-enabled medical technologies. ITA 
invites applications from industry representatives to participate in 
the roundtables. Applicants should be existing producers/providers or 
prospective new market entrants in the AI-enabled medical technology 
sector with solutions that are or will be produced or developed in the 
United States and exported overseas.

DATES: 
    Event: The roundtable will be held on Wednesday, October 30, 2024, 
from 2:30 p.m. to 4:30 p.m., Eastern Daylight Time.
    Event Registration: ITA will evaluate registrations based on the 
submitted information (see below) and inform applicants of selection 
decisions, which will be made on a rolling basis until a maximum of 20 
participants have been selected.

ADDRESSES: 
    Event: The roundtable will be held via Microsoft Teams, and the 
link for the meeting will be provided to selected and registered 
participants.

FOR FURTHER INFORMATION CONTACT: Liam Kraft at 771-216-4432 or via 
email at [email protected].

SUPPLEMENTARY INFORMATION: AI is anticipated to yield significant 
growth opportunities for the healthcare sector. With AI regulation and 
policy formation still nascent in many markets, it is important to 
understand the implications of changes in these areas for U.S. 
healthcare industry stakeholders as governments, practitioners, and 
patients increasingly adopt AI solutions in healthcare and as demand 
for AI-enabled medical technologies grows in overseas markets. This 
discussion will help position ITA to work with U.S. industry 
stakeholders in ways that can enhance U.S. industry competitiveness in 
overseas markets and reduce current or future trade barriers faced by 
companies in this space.
    The Department seeks individual input and views at the 10/30/2024 
roundtable regarding overseas competitiveness of U.S. companies 
producing, or planning to produce, and exporting AI-enabled medical 
technologies. Participants will be encouraged to provide any relevant 
feedback on this issue during the roundtable, which may include 
comments on the following non-exhaustive list of possible topics:
     With the introduction of technologies such as foundational 
models and general-purpose AI, what are the implications of regulatory 
and policy shifts in markets to which your company exports AI-enabled 
medical technologies, and how have these changes affected your 
company's competitiveness?
     Which markets, given shifting regulatory and policy 
landscapes, present the most conducive environment for the 
competitiveness of U.S. AI-enabled medical technologies, from your 
experience?
     How do you assess the potential for public-private 
partnerships (P3s) to support efforts in the healthcare sector to 
deliver AI-enabled medical technologies to overseas markets? What would 
a successful P3 in this space look like? What kind of resources are 
needed from the U.S. Government to enable this success?
     What kinds of strategic international engagements do you 
believe would be most effective in supporting U.S. providers of AI-
enabled medical technologies and their competitiveness in overseas 
markets?
     What kinds of trade barriers are you seeing negatively 
affect U.S. competitiveness for AI-enabled medical technologies in 
overseas markets? Where do you encounter these barriers? How do you 
think the barriers can be reduced, removed, or prevented?
    [cir] What are the implications of regulations/policies around 
health data in foreign markets for U.S. competitiveness in AI-enabled 
medical technologies that you're seeing in your work?
    The event is closed to press and the public. Industry participation 
is limited to a maximum of 20 qualifying industry representatives.

Selection

    To attend, participants should submit the below information to 
[email protected] by no later than 10/23/2024. ITA will evaluate 
registrations based on the submitted information (and based on the 
criteria below) on a rolling basis until a maximum of 20 participants 
have been selected and inform applicants of selection decisions.
    Applicants are encouraged to send representatives at a sufficiently 
senior level to be knowledgeable about their company's capabilities, 
interests, and challenges in the global market of AI-enabled medical 
technologies. Due to time constraints, there is a limit of one person 
to speak on behalf of each company.
    Applicants should include the following information in their 
response email:
     Name of attendee and short bio.
     Name of company and brief company description.
     A statement self-certifying how the company meets each of 
the following criteria:
    1. It is not majority owned by a foreign government entity (or 
entities).
    2. It is an existing provider or prospective new market entrant, of 
AI-enabled medical technologies that are or will be produced in the 
United States in one or more of the following segments: Machine 
learning, natural language processing, clinical, disease detection, 
medical imaging, personalized care, patient monitoring, robotics, or 
healthcare administration.
    3. The representative will be able to attend the entire roundtable.
    Selection will be based on the following criteria:
     The company's production or production plans with respect 
to AI-enabled medical technologies.
     The company's experience in exporting AI-enabled medical 
technologies from the United States to overseas markets.
     Suitability of the representative's position and biography 
to be able to engage in the conversation.
     Ability of the company to contribute to the roundtable's 
purpose of seeking individual input and views on policies and 
initiatives that strengthen U.S. industry competitiveness of U.S. 
exports.

    Dated: August 20, 2024.
Amanda Lawrence,
Acting Director, Office of Health Industries, International Trade 
Administration.
[FR Doc. 2024-19040 Filed 8-26-24; 8:45 am]
BILLING CODE 3510-DR-P